The
glycine co-agonist binding site of the N-methyl-D-aspartat (
NMDA) receptor is discussed as an interesting target for different
central nervous system diseases. Antagonism at this co-agonist site has been suggested as an alternative to the use of non-competitive or competitive
NMDA receptor antagonists, which are associated with a pronounced adverse effect profile in chronic
epilepsy models and
epilepsy patients. In the present study, we addressed the hypothesis that sub-chronic administration of the
glycine-binding site antagonist
L-701,324 might exert disease-modifying effects in fully kindled mice during a period with frequent seizure elicitation (massive kindling). Moreover, we analyzed whether
L-701,324 exposure during this phase affects the subsequent response to an
antiepileptic drug.
L-701,324 treatment during the massive kindling phase did not affect ictogenesis. Mean seizure severity and cumulative seizure duration proved to be comparable between vehicle- and L-701,324-treated mice. Following withdrawal of
L-701,324 seizure thresholds did not differ in a significant manner from those in animals that received vehicle
injections. A low dosage of
phenobarbital caused a significant increase of the
generalized seizure threshold in the
L-701,324 pre-treated group, whereas it did not exert a comparable effect in animals that received vehicle during the massive kindling phase. Analysis of
P-glycoprotein in the hilus of the hippocampus revealed lower expression rates in
L-701,324 pre-treated kindled mice. In conclusion, the data indicate that targeting of the
NMDA receptor glycine-binding site does not result in
anticonvulsant or disease-modifying effects. However, it might improve
antiepileptic drug responses. The findings might be linked to an impact on
P-glycoprotein expression. However, future studies are necessary to further evaluate the mechanisms and assess the potential of respective add-on approaches.